Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Descourt R, Pérol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot AB, Guisier F, Galland L, Do P, Schott R, Dansin É, Arrondeau J, Auliac JB, Geier M, Chouaïd C. Descourt R, et al. Among authors: arrondeau j. Cancers (Basel). 2022 Mar 30;14(7):1751. doi: 10.3390/cancers14071751. Cancers (Basel). 2022. PMID: 35406523 Free PMC article.
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L, Sakka M, Retbi A, Bouam S, Hassani L, Meritet JF, Rufat P, Bonnefont-Rousselot D, Batista R, Terris B, Bellanger A, Thabut D, Vozy A, Spano JP, Coriat R, Goldwasser F, Aractingi S, Sogni P, Pol S, Mallet V; CERTIM Research Group; DEMOSTHENES Research Group. Parlati L, et al. JHEP Rep. 2023 Aug 12;5(12):100880. doi: 10.1016/j.jhepr.2023.100880. eCollection 2023 Dec. JHEP Rep. 2023. PMID: 38074948 Free PMC article.
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C. Auliac JB, et al. Among authors: arrondeau j. Lung Cancer. 2019 Jan;127:96-102. doi: 10.1016/j.lungcan.2018.11.037. Epub 2018 Nov 27. Lung Cancer. 2019. PMID: 30642559
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C. Descourt R, et al. Among authors: arrondeau j. Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14. Lung Cancer. 2019. PMID: 31491676 Free article.
Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?
Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B. Bellesoeur A, et al. Among authors: arrondeau j. Cancers (Basel). 2019 Nov 13;11(11):1784. doi: 10.3390/cancers11111784. Cancers (Basel). 2019. PMID: 31766292 Free PMC article.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Tiako Meyo M, et al. Among authors: arrondeau j. Cancers (Basel). 2020 Feb 18;12(2):473. doi: 10.3390/cancers12020473. Cancers (Basel). 2020. PMID: 32085544 Free PMC article.
Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.
Fournel L, Boudou-Rouquette P, Prieto M, Hervochon R, Guinet C, Arrondeau J, Alexandre J, Damotte D, Wislez M, Batteux F, Icard P, Goldwasser F, Alifano M. Fournel L, et al. Among authors: arrondeau j. Cancer Chemother Pharmacol. 2020 Oct;86(4):497-505. doi: 10.1007/s00280-020-04142-9. Epub 2020 Sep 16. Cancer Chemother Pharmacol. 2020. PMID: 32936316
Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris.
Tlemsani C, Arrondeau J, De Percin S, Gataa I, Bretagne M, Ajgal Z, Huillard O, Wislez M, Coriat R, Alexandre J, Boudou-Rouquette P, Goldwasser F. Tlemsani C, et al. Among authors: arrondeau j. Clin Med (Lond). 2021 Sep;21(5):e552-e555. doi: 10.7861/clinmed.2020-0666. Epub 2021 Aug 2. Clin Med (Lond). 2021. PMID: 34341004 Free PMC article.
66 results